SYDNEY, Monday, 22 April 2013: Cellmid Limited (ASX:CDY) provides the following comments in relation to the attached Appendix 4C form:
- Cellmid’s operating cash outflows remained steady during 3Q2013 at $565,000 ($545,000 in 2Q2013).
- The Company had proceeds of $2,006,000 during the quarter from issuing shares pursuant to a private placement. This was a major contributor to the $1,441,000 net increase in the cash held at the end of the period ($22,000 in 2Q2013).
- During 3Q2013 Cellmid received $100,000 from Fujikura Kasei, which was 50% of the consideration for the Option Agreement to license the Company’s midkine cancer diagnostic assets for Japan. The other $100,000 of the consideration was received in April consistent with the terms of the Option Agreement.
- During the reporting period Cellmid, via its subsidiary Advangen International Pty Ltd, received $48,000 from customers. Consistent with early expectations the Company has to date recorded net receipts of $334,000.
For further information please download PDF below:
